Entrada Therapeutics Inc (TRDA)
17.74
+0.14
(+0.82%)
USD |
NASDAQ |
Nov 04, 16:00
17.76
+0.01
(+0.06%)
After-Hours: 20:00
Entrada Therapeutics Enterprise Value: 184.97M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 184.97M |
| October 31, 2024 | 167.86M |
| October 30, 2024 | 171.20M |
| October 29, 2024 | 173.06M |
| October 28, 2024 | 176.41M |
| October 25, 2024 | 162.28M |
| October 24, 2024 | 156.70M |
| October 23, 2024 | 161.53M |
| October 22, 2024 | 167.48M |
| October 21, 2024 | 174.55M |
| October 18, 2024 | 179.02M |
| October 17, 2024 | 186.08M |
| October 16, 2024 | 187.20M |
| October 15, 2024 | 182.36M |
| October 14, 2024 | 193.52M |
| October 11, 2024 | 154.46M |
| October 10, 2024 | 118.38M |
| October 09, 2024 | 131.77M |
| October 08, 2024 | 139.96M |
| October 07, 2024 | 145.54M |
| October 04, 2024 | 165.25M |
| October 03, 2024 | 141.82M |
| October 02, 2024 | 136.24M |
| October 01, 2024 | 125.45M |
| September 30, 2024 | 124.70M |
| Date | Value |
|---|---|
| September 27, 2024 | 142.19M |
| September 26, 2024 | 116.89M |
| September 25, 2024 | 90.11M |
| September 24, 2024 | 103.13M |
| September 23, 2024 | 72.25M |
| September 20, 2024 | 76.34M |
| September 19, 2024 | 88.25M |
| September 18, 2024 | 38.03M |
| September 17, 2024 | 57.00M |
| September 16, 2024 | 71.51M |
| September 13, 2024 | 88.25M |
| September 12, 2024 | 83.04M |
| September 11, 2024 | 83.04M |
| September 10, 2024 | 77.83M |
| September 09, 2024 | 89.36M |
| September 06, 2024 | 80.81M |
| September 05, 2024 | 102.76M |
| September 04, 2024 | 103.13M |
| September 03, 2024 | 112.43M |
| August 30, 2024 | 188.69M |
| August 29, 2024 | 181.25M |
| August 28, 2024 | 137.35M |
| August 27, 2024 | 151.49M |
| August 26, 2024 | 159.30M |
| August 23, 2024 | 144.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-91.70M
Minimum
May 09 2022
971.53M
Maximum
Nov 17 2021
163.69M
Average
141.52M
Median
Oct 02 2023
Enterprise Value Benchmarks
| Fulcrum Therapeutics Inc | -73.47M |
| Sarepta Therapeutics Inc | 11.52B |
| Catalyst Pharmaceuticals Inc | 2.222B |
| Vertex Pharmaceuticals Inc | 115.80B |
| Regenxbio Inc | 144.07M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 55.03M |
| Revenue (Quarterly) | 94.69M |
| Total Expenses (Quarterly) | 41.27M |
| EPS Diluted (Quarterly) | 1.55 |
| Profit Margin (Quarterly) | 58.11% |
| Earnings Yield | 16.68% |
| Operating Earnings Yield | 15.22% |
| Normalized Earnings Yield | 16.68 |